Drug-resistance patterns assessed from tumor marker analysis

Area of Science:

• Oncology
• Biochemistry
• Mathematical Biology

Background:

• Nonseminomatous germ cell tumors (NSGCTs) are a significant group of cancers.
• Tumor markers like alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) are crucial for monitoring treatment response.
• Understanding tumor cell kinetics and resistance mechanisms is vital for effective NSGCT treatment.

Purpose of the Study:

• To analyze tumor marker kinetics (AFP and hCG) during NSGCT treatment.
• To compare observed fractional tumor kill patterns with theoretical models of tumor growth and drug resistance.
• To identify a mathematical model that accurately describes tumor response to therapy in NSGCT patients.

Main Methods:

• Analysis of AFP and hCG levels in 19 NSGCT patients undergoing treatment.
• Calculation of fractional tumor kill per cycle, assuming exponential tumor growth and marker decay.
• Evaluation of tumor marker production reflecting clonogenic tumor size.
• Comparison of observed data against Skipper and Goldie-Coldman resistance models, and a novel multi-clone model.

Main Results:

• Both the Skipper and Goldie-Coldman models predicted a faster tumor kill rate than observed in patients.
• A model incorporating four distinct tumor cell clones with varying sensitivities accurately described the observed tumor marker decrease.
• This suggests a complex initial tumor cell population heterogeneity in NSGCTs.

Conclusions:

• The presence of multiple, differentially sensitive tumor cell clones at treatment initiation is a key factor in NSGCT response.
• Simple models of tumor resistance do not adequately explain the observed treatment dynamics in NSGCTs.
• A more complex model accounting for initial clonal heterogeneity is necessary for understanding and predicting treatment outcomes in NSGCTs.